<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21576">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825992</url>
  </required_header>
  <id_info>
    <org_study_id>CL-AF-002</org_study_id>
    <nct_id>NCT02825992</nct_id>
  </id_info>
  <brief_title>Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation</brief_title>
  <acronym>UNCOVER-AF</acronym>
  <official_title>Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation (UNCOVER-AF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acutus Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acutus Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post Market Clinical Follow-up Study designed to evaluate the incidence of device- and
      procedure-related safety, efficacy, and efficiency (6 and 12 month outcomes) when using the
      AcQMap™ as an imaging and mapping system for ablation of persistent atrial fibrillation
      (AF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, single-arm, multi-center, multi-national, non-randomized, post-market study
      designed to provide clinical data regarding the use of the AcQMap™ System in the ablation of
      persistent atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>freedom from device/procedure related Major Adverse Events (MAEs)</measure>
    <time_frame>24 hours</time_frame>
    <description>MAEs include: Death, cardiac perforation, cerebral infarct, systemic embolism, major bleeding, cardiac valve damage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Recording of all adverse events in 12 month follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>24 hours</time_frame>
    <description>Conversion to sinus rhythm post ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>6, 9, and 12 Months</time_frame>
    <description>Freedom from AF</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>AcQMap System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Use of the AcQMap System for imaging and mapping of atrial chambers during AF ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcQMap System</intervention_name>
    <description>3D imaging and mapping system for cardiac chambers</description>
    <arm_group_label>AcQMap System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for an ablation of persistent atrial fibrillation

        Exclusion Criteria:

          -  Any duration of continuous AF lasting longer than 12 months

          -  Previous AF ablation

          -  Significant structural heart disease

          -  Previous cerebral infarct

          -  Major bleeding disorders

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Willems, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf (UKE)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerald Cox, PA</last_name>
    <phone>442.232-6080</phone>
    <email>jerry.cox@acutusmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deana Pierce</last_name>
    <phone>442.232-6080</phone>
    <email>deana.pierce@acutus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huseyin Ince, MD</last_name>
    </contact>
    <investigator>
      <last_name>Huseyin Ince, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Cologne</city>
        <zip>D-50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Steven, MD</last_name>
      <phone>+49 221 478 32396</phone>
      <email>daniel.steven@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Steven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Willems, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kathrin Heitmann</last_name>
    </contact_backup>
    <investigator>
      <last_name>Stephan Willems, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Tondo, MD</last_name>
      <email>ctondo@ccfm.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Tondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Pison, MD</last_name>
      <phone>+31 43 387 7095</phone>
      <email>l.pison@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Laurent Pison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucas Boermsa, MD</last_name>
      <email>l.boersma@antoniusziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Michael Bosschaert</last_name>
      <phone>+31 30 609 22 78</phone>
      <email>m.bosschaert@antoniusziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Lucas Boermsa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Grace, MD</last_name>
      <phone>+44 1223 333 631</phone>
      <email>aag1000@cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Becky McClean</last_name>
      <phone>+44 1480 364 787</phone>
      <email>Rebecca.McClean@papworth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Grace, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wong, MD</last_name>
      <email>tom.wong@ic.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Thomas Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Betts, MD</last_name>
      <phone>+44 1865 220 256</phone>
      <email>tim.betts@ouh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Douthwaite, RN</last_name>
      <phone>+44 1865 223 173</phone>
      <email>Rebecca.Douthwaite@ouh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Tim Betts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Tyne and Wear</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Murray, MD</last_name>
      <phone>+44 1912 448 988</phone>
      <email>Stephen.murray@NUTH.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Steven Steven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>July 5, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
